focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

Mon, 14th Nov 2022 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Hutchmed (China) Ltd, up 13% at 184.96 pence, 12-month range 1.30p - 194.00p. The Hong Kong-based biopharmaceutical company reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. The drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase three study in 703 patients, which the firm explains is clinically meaningful. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

----------

Midatech Pharma PLC, up 7.2% at 6.49 pence, 12-month range 6.00p - 24.63p. Enrols the first patient into its phase one study of MTX-110 in recurrent glioblastoma, a type of cancer that appears in the brain or spinal cord. The study is an open-label, dose escalation study to assess the feasibility and safety of intermittent infusions of MTX-100. Cardiff-based biotechnology firm Midatech says it previously reported "encouraging results" from a phase one study of MTX-110 in diffuse intrinsic pontine glioma, a type of tumour that is located on the brain stem.

----------

SRT Marine Systems PLC, up 7.6% at 48.95 pence, 12-month range 23.60p - 55.00p. The maritime surveillance, analytics and management systems developer reports a steep increase in interim revenue as it swings to a pretax profit of GBP2.1 million from a loss of GBP3.1 million. In the six months to September 30, SRT Marine Systems reports revenue of GBP18.8 million, multiplied from GBP4.7 million the previous year. This, it adds, is despite ongoing component supply issues. Chief Executive Simon Tuckers expects this strong performance to continue going forward as long-term demand stays robust.

----------

AIM - LOSERS

----------

Tremor International Ltd, down 26% at 281.00 pence, 12-month range 2.90p - 330.60p. Swings to a total comprehensive IFRS loss of USD5.2 million in the three months ended September 30, from a profit of USD10.2 million the previous year. Revenue in the quarter drops 19% year-on-year to USD70.9 million from USD87.0 million. Despite the drop in profit and revenue, Tremor says it remains "well-positioned" to benefit from "anticipated industry secular growth trends" which it expects to help mitigate potential negative effects. Full-year adjusted earnings before interest, taxation, depreciation, and amortization is expected at USD140 million.

----------

Shanta Gold Ltd, down 12% at 9.60 pence, 12-month range 6.50p - 14.00p. Three companies which previously expressed interest in the East Africa-focused gold producer, developer and explorer say they do not intend to make an offer for the firm. In October, Shanta received approaches from Shandong Gold Group Co Ltd, Yintai Gold Co Ltd and Chaarat Gold Holdings Ltd. These companies have since decided not to proceed with an offer. Nonetheless, Shanta says it continues to believe in the strength of its business and the potential of its portfolio.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 Apr 2016 12:20

Midatech Pharma Announces Launch Of Zuplenz In US

Read more
6 Jan 2016 10:18

WINNERS & LOSERS SUMMARY: ARM Hit By iPhone Production Cut Report

Read more
6 Jan 2016 07:57

Midatech Pharma 2015 Revenue To Come In Ahead Of Expectations

Read more
4 Jan 2016 14:18

Midatech particle technology to be used in vaccines

(ShareCast News) - Midatech Pharma's proprietary technology received a boost on Monday, with the news it had signed a licensing agreement with a private British biotechnology company. The AIM-listed pharmaceutical company - focused on products in oncology and other therapeutic areas - reported it ha

Read more
4 Jan 2016 07:35

Midatech Pharma Signs Licensing Deal With Emergex Vaccines

Read more
18 Dec 2015 09:53

Midatech Pharma Agrees To Buy Zuplenz From Galena Biopharma

Read more
18 Dec 2015 09:39

BROKER RATINGS SUMMARY: UBS Initiates Restaurant Group At Buy

Read more
14 Dec 2015 08:28

Midatech Pharma Appoints Centurion Pharma For Q-Octreotide In Turkey

Read more
4 Dec 2015 09:33

BROKER RATINGS SUMMARY: Barclays Downgrades Whitbread To Equal Weight

Read more
19 Nov 2015 10:00

Midatech Pharma Files Supplemental Disclosure In Relation To DARA Buy

Read more
15 Sep 2015 08:42

BROKER RATINGS SUMMARY: UBS Initiates Legal & General With Sell

Read more
14 Sep 2015 08:08

Midatech Pharma Loss Widens On Acquisition Costs, Investment

Read more
13 Aug 2015 07:00

Midatech Signs Deal With Eye Disesases Company Ophthotech

Read more
23 Jul 2015 08:04

Midatech Pharma Begins Phase IIa Study For MSL-001

Read more
23 Jun 2015 14:57

DIRECTOR DEALINGS: Midatech Pharma Finance Director Buys 500 Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.